Back

Colchicine: who benefits?

31 August 2026 (08:51 - 09:09)
Organised by: Logo
Congress Presentation Part of: Assessing and treating 'residual risk' beyond low-density lipoproteins Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jean-Claude Tardif

Montreal Heart Institute, Montreal (Canada)

4 More presentations in this session

Presentation thumbnail
Optimal ways to identify high-risk cohorts beyond low-density lipoproteins: unmet high-risk patients
Doctor P. Ridker (Boston, US)
Slides Video
Presentation thumbnail
Targeting lipoprotein(a)
Professor B. Nordestgaard (Copenhagen, DK)
Slides Video
Presentation thumbnail
GLP1 agonist: for everyone?
Professor E. Michos (Baltimore, US)
Slides Video
Presentation thumbnail
Assessing and treating 'residual risk' beyond low-density lipoproteins - discussion
Video

Access the full session

Session thumbnail
Assessing and treating 'residual risk' beyond low-density lipoproteins
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 08:51 CET
You may be interested in
thumbnail
Congress Presentation
Colchicine: do we need more evidence?
31 August 2025
thumbnail
Congress Presentation
Inflammation as a therapeutic target in atherosclerosis: what do we know about residual inflammation and available treatments?
28 August 2026
thumbnail
Congress Presentation
Anti-inflammatory effects of atorvastatin and colchicine combination in patients with acute or chronic coronary syndrome undergoing coronary angiography and/or PCI
28 August 2026
thumbnail
Congress Presentation
Comparative effectiveness of anti-inflammatory therapies for atherosclerotic cardiovascular disease: a systematic review and network meta-analysis of 16 randomised trials
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources